Donald Trump’s journey from business magnate to U.S. president is one of high ambition and public visibility. As a real estate developer, media personality, and politician, Trump left an ...
BioMarin's has signed the first contract with an insurer in Germany for Roctavian, its recently approved gene therapy for haemophilia A, as it tests out its outcomes-based agreement (OBA ...
Nov. 4, 2024 — Researchers used genomics to investigate the genetic changes causing resistance to transgenic crops in field populations of the corn earworm, also ...
BioMarin Pharma has decided not to divest its haemophilia A gene therapy Roctavian, which has struggled to build much traction in the market, but is reining back its ambitions for the business.
Biophotonics is the study of optical processes in biological systems, both those that occur naturally and in bioengineered materials. A particularly important aspect of this field is imaging and ...
BioMarin Pharmaceutical (BMRN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great ...